101 related articles for article (PubMed ID: 22755276)
1. Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers.
Abbas Z; Raza S; Hamid S; Jafri W
J Pak Med Assoc; 2012 Apr; 62(4):338-43. PubMed ID: 22755276
[TBL] [Abstract][Full Text] [Related]
2. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
[TBL] [Abstract][Full Text] [Related]
3. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
4. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
6. Induction doses of interferon-alpha-2a in combination with ribavirin and/or amantadine for the treatment of chronic hepatitis C in non-responders to interferon monotherapy: a randomized trial.
Salmerón J; Diago M; Andrade R; Pérez R; Solá R; Romero M; de la Mata M; Granados R; Ruiz-Extremera A; Muñoz de Rueda P
J Viral Hepat; 2007 Feb; 14(2):89-95. PubMed ID: 17244248
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind controlled trial of interferon alpha-2b and ribavirin vs. interferon alpha-2b and amantadine for treatment of chronic hepatitis C non-responder to interferon monotherapy.
Younossi ZM; Mullen KD; Zakko W; Hodnick S; Brand E; Barnes DS; Carey WD; McCullough AC; Easley K; Boparai N; Gramlich T
J Hepatol; 2001 Jan; 34(1):128-33. PubMed ID: 11211889
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C.
Teuber G; Pascu M; Berg T; Lafrenz M; Pausch J; Kullmann F; Ramadori G; Arnold R; Weidenbach H; Musch E; Junge U; Wiedmann KH; Herrmann E; Zankel M; Zeuzem S
J Hepatol; 2003 Oct; 39(4):606-13. PubMed ID: 12971972
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of interferon-alpha high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C.
Berg T; Naumann U; Wiedenmann B; Hopf U
Z Gastroenterol; 2001 Feb; 39(2):145-51. PubMed ID: 11253505
[TBL] [Abstract][Full Text] [Related]
10. Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.
Santantonio T; Fasano M; Sagnelli E; Tundo P; Babudieri S; Fabris P; Toti M; Di Perri G; Marino N; Pizzigallo E; Angarano G;
Hepatology; 2014 Jun; 59(6):2101-9. PubMed ID: 24442928
[TBL] [Abstract][Full Text] [Related]
11. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
[TBL] [Abstract][Full Text] [Related]
12. Prolonged interferon treatment after combination interferon and ribavirin therapy in patients with chronic hepatitis C: a clinical trial of interferon relapsers and non-responders.
Kao JH; Lai MY; Chen PJ; Cheng YM; Chen DS
J Formos Med Assoc; 2001 Oct; 100(10):662-7. PubMed ID: 11760371
[TBL] [Abstract][Full Text] [Related]
13. Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine.
Stauber RE; Hofer H; Hackl F; Schütze K; Datz C; Hegenbarth K; Jessner W; Steindl-Munda P; Peter F;
Wien Klin Wochenschr; 2004 Aug; 116(15-16):530-5. PubMed ID: 15471180
[TBL] [Abstract][Full Text] [Related]
14. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
[TBL] [Abstract][Full Text] [Related]
16. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
[TBL] [Abstract][Full Text] [Related]
17. Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure.
Foster GR; Zeuzem S; Andreone P; Pol S; Lawitz EJ; Diago M; Roberts S; Pockros PJ; Younossi Z; Lonjon-Domanec I; De Meyer S; Luo D; George S; Beumont M; Picchio G
J Hepatol; 2013 Mar; 58(3):488-94. PubMed ID: 23183521
[TBL] [Abstract][Full Text] [Related]
18. Effects of alpha interferon induction plus ribavirin with or without amantadine in the treatment of interferon non-responsive chronic hepatitis C: a randomised trial.
Adinolfi LE; Utili R; Tonziello A; Ruggiero G
Gut; 2003 May; 52(5):701-5. PubMed ID: 12692056
[TBL] [Abstract][Full Text] [Related]
19. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI).
Maynard M; Pradat P; Bailly F; Rozier F; Nemoz C; Si Ahmed SN; Adeleine P; Trépo C;
J Hepatol; 2006 Mar; 44(3):484-90. PubMed ID: 16426697
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
Chen J; Shi J; Xie WF; Zeng X; Lin Y
Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
